Katherine High, Spark Therapeutics to give Keynote Address at GTCbio's Ocular Conference
Katherine High will discuss Spark Therapeutics' Phase 3 trial for RPE65-mediated inherited retinal dystrophy at GTCbio's Ocular Diseases Drug Discovery Meeting.
- San Diego, CA (1888PressRelease) March 22, 2016 - Katherine High is the President and Chief Scientific Officer at Spark Therapeutics and is also the Professor of Pediatrics at The Children's Hospital of Philadelphia. Dr. High's keynote presentation will concentrate on Spark Therapeutics' Phase 3 trial for RPE65-mediated inherited retinal dystrophy at GTCbio's 8th Ocular Diseases Drug Discovery Meeting on March 21-22, 2016 in San Diego, CA.
Katherine A. High, M.D. has a world renowned background and expertise in hematology, hemostasis and thrombosis, and gene therapy. Dr. High started her career in research on the molecular basis of blood coagulation and therapies in bleeding disorders. Her efforts in the response of AAV vectors for gene therapy in hemophilia have led to bench-to-bedside results. Katherine's academic achievements and experience includes participation on the FDA Advisory Committee on Cell, Tissue and Gene Therapies, past president of ASGCT, an A.B. in Chemistry at Harvard University, a M.D. and business certification from UNC, and a master's degree from UPenn.
The 8th Ocular Diseases Drug Discovery Conference brings together a mix of academic and industry authoritative experts from leading affiliations (such as GlaxoSmithKline, Clearside Biomedical, Sanofi-Genzyme, AGTC, National Eye Institute, Oregon Health & Science University etc.) to cover many current and relevant aspects of novel targets, sustained release drug delivery, regenerative medicine, and its application to ocular health.
For more information please visit this website: www.gtcbio.com/ocular/agenda
GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com
Email: infogtcbio ( @ ) gtcbio dot com
Phone: (626) 256-6405
Fax: (626) 466-4433
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam